Comparative Pharmacology
Head-to-head clinical analysis: AMPHADASE versus HYLENEX RECOMBINANT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHADASE versus HYLENEX RECOMBINANT.
AMPHADASE vs HYLENEX RECOMBINANT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMPHADASE contains amphetamines which increase synaptic dopamine and norepinephrine by inhibiting reuptake and reversing their transporters.
HYLENEX RECOMBINANT is a recombinant human hyaluronidase that depolymerizes hyaluronan, a glycosaminoglycan in the extracellular matrix. By hydrolyzing hyaluronan, it temporarily increases tissue permeability and reduces the viscosity of hyaluronan, facilitating the dispersion and absorption of co-administered drugs or fluids.
1 mg intramuscularly or subcutaneously daily
Subcutaneous or intradermal injection of 1 mL (150 U) at the site of extravasation or hyaluronic acid filler complication; may repeat if no improvement within 30-60 minutes.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours (mean 10 hours); clinically, steady-state achieved within 2-3 days
Terminal half-life approximately 2.5 hours (range 2-3 hours); duration of enzymatic effect correlates with half-life, with clinically significant hyaluronidase activity lasting 24-48 hours.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination of metabolites (20-30%)
Primarily metabolized by proteolysis in the liver and kidneys; less than 2% excreted unchanged in urine; no significant biliary or fecal elimination.
Category C
Category C
Hyaluronidase
Hyaluronidase